FDA Approves First Treatment for Stem Cell Transplant–Associated Thrombotic Microangiopathy

The U.S. Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab‑wuug), marking the first authorized therapy for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA) in adults and children aged 2…

Continue Reading FDA Approves First Treatment for Stem Cell Transplant–Associated Thrombotic Microangiopathy